← Back to Search

Ablation Therapy

Endocardial vs Epicardial Ablation for Atrial Fibrillation (REPEAL-AF Trial)

N/A

Waitlist Available

Research Sponsored by University of Rochester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 1 year

Awards & highlights

REPEAL-AF Trial Summary

This trial will compare two treatments for people with atrial fibrillation that has come back after a previous treatment. One treatment is redo PVI, which is a repeat of the previous treatment. The other treatment is hybrid epicardial ablation, which is a new treatment that also includes isolation of the left atrial appendage.

Eligible Conditions

Recurrent Paroxysmal Atrial Fibrillation Despite Prior Pulmonary Vein Isolation

REPEAL-AF Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Atrial fibrillation > 30 secs

REPEAL-AF Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVIExperimental Treatment1 Intervention

Minimally invasive surgical hybrid ablation using the convergent approach plus LAA exclusion using the clip

Group II: Endocardial PVIActive Control1 Intervention

Endocardial complete PVI

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor

836 Previous Clinical Trials

518,168 Total Patients Enrolled

Meshalkin Research Institute of Pathology of CirculationNETWORK

115 Previous Clinical Trials

25,112 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the criteria necessary to take part in this clinical venture?

"This medical study requires 162 individuals with pulmonary veins, aged between 18 and 80. Additionally, they must have a left atrium diameter smaller than 6 cm on transthoracic echo imaging. Furthermore, these participants should be symptomatic of paroxysmal AF (lasting up to 7 days before spontaneous resolution) despite having had one or two PVI procedures in the past decade; furthermore, they need to meet current guidelines for being referred for re-ablation."

Answered by AI

Does this research protocol admit seniors aged seventy-five and over?

"The parameters of this clinical trial preclude anyone under 18 or over 80 from enrolling; however, there are 171 trials that cater to minors and 1366 studies suitable for older adults."

Answered by AI

Are participants being accepted to partake in this experiment?

"It is confirmed that this clinical trial, which first appeared on the 10th of October 2023 and was amended lastly on 8th October 2022, no longer seeks patients. However, 1493 other studies across multiple domains are currently recruiting volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Endocardial Vs Epicardial Ablation for Recurrent Paroxysmal AF

Jonathan Steinberg 2025. "Endocardial Vs Epicardial Ablation for Recurrent Paroxysmal AF". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04506814.